Michael Lein
Overview
Explore the profile of Michael Lein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stephan C, Ralla B, Bonn F, Diesner M, Lein M, Jung K
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326710
There are limited and discrepant data on prostate cancer (PCa) and vitamin D. We investigated changes in three vitamin D metabolites in PCa patients after prostatectomy with zoledronic acid (ZA)...
2.
Peters R, Stephan C, Jung K, Lein M, Friedersdorff F, Maxeiner A
Urol Int
. 2021 Aug;
106(9):878-883.
PMID: 34433176
Background: Beyond prostate-specific antigen (PSA), other biomarkers for prostate cancer (PCa) detection are available and need to be evaluated for clinical routine. Objective: The aim of the study was to...
3.
Stephan C, Jung K, Lein M, Rochow H, Friedersdorff F, Maxeiner A
World J Urol
. 2021 Jan;
39(9):3273-3279.
PMID: 33471165
Purpose: To evaluate the Prostate Health Index (PHI) density (PHID) in direct comparison with PHI in a prospective large cohort. Methods: PHID values were calculated from prostate-specific antigen (PSA), free...
4.
Tolle A, Jung K, Friedersdorff F, Maxeiner A, Lein M, Fendler A, et al.
Cancer Biomark
. 2020 Dec;
30(4):381-393.
PMID: 33361585
Background: There is an urgent need for better prostate cancer (PCa) biomarkers due to the low specificity of prostate specific antigen (PSA). Objective: Prostate Health Index (PHI) is an advanced...
5.
Zhao Z, Weickmann S, Jung M, Lein M, Kilic E, Stephan C, et al.
Cancers (Basel)
. 2019 Oct;
11(10).
PMID: 31640261
Within five to ten years after radical prostatectomy (RP), approximately 15-34% of prostate cancer (PCa) patients experience biochemical recurrence (BCR), which is defined as recurrence of serum levels of prostate-specific...
6.
Stephan C, Lein M, Matalon J, Kilic E, Zhao Z, Busch J, et al.
J Urol
. 2016 Mar;
196(3):709-14.
PMID: 26976204
Purpose: We evaluated the usefulness of serum 25-hydroxyvitamin D as a marker of aggressive prostate cancer and for active surveillance compared to PHI (Prostate Health Index). Materials And Methods: Of...
7.
Meller S, Meyer H, Bethan B, Dietrich D, Gonzalez Maldonado S, Lein M, et al.
Oncotarget
. 2015 Dec;
7(2):1421-38.
PMID: 26623558
Integrated analysis of metabolomics, transcriptomics and immunohistochemistry can contribute to a deeper understanding of biological processes altered in cancer and possibly enable improved diagnostic or prognostic tests. In this study,...
8.
Lobo G, Monasterios M, Rodrigues J, Gamboa N, Capparelli M, Martinez-Cuevas J, et al.
Eur J Med Chem
. 2015 Apr;
96:281-95.
PMID: 25899333
A highly regiospecific synthesis of a series of indenoindoles is reported, together with X-ray studies and their activity against human prostate cancer cells PC-3 and LNCaP in vitro. The most...
9.
Stephan C, Wilkosz J, Rozanski W, Ecke T, Lein M, Brys M, et al.
Clin Chem Lab Med
. 2014 Oct;
53(3):477-83.
PMID: 25274944
Background: In 2013, thiosulfate in urine has been proposed as promising prostate cancer (PCa) biomarker. However, a missing comparison with other proven PCa markers suggested a re-evaluation study. Therefore, together...
10.
Jung K, Lein M
Biochim Biophys Acta
. 2014 Sep;
1846(2):425-38.
PMID: 25220832
Bone metastases are characterized by increased osteoblastic and/or osteolytic processes depending on the tumor type. The altogether destructive effect of metastasis formation promoted by increased metabolic activity raises the release...